[1] Van Den Neste, E., Bontemps, F., Delacauw, A., Cardoen, S., Louviaux, I., Scheiff, J.-M., Gillis, E. Leveugle, P., Deneys, V., Ferrant, A., Van Den Berghe, G. (1999) Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2’-deoxyadenosine. Leukemia 13, 918-25.

[2] Van Den Neste, E., Louviaux, I., Michaux, J.-L., Delannoy, A., Michaux, L., Sonet, A., Bosly, A., Doyen, C., Mineur, P., André, M., Straetmans, N., Coche, E., Venet, C., Duprez, T., Ferrant, A. (2000) Phase I/II study of 2-chloro-2’-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma. Leukemia 14, 1136-42.

[3] Bontemps, F., Delacauw, A., Cardoen, S., Van Den Neste, E., Van den Berghe, G. (2000) Metabolism and cytotoxic effects of 2-chloroadenine, the major catabolite of 2-chloro-2'-deoxyadenosine. Biochem. Pharmacol. 59, 1237-43.

[4] Cardoen, S., Van Den Neste, E., Smal, C., Rosier, J.-F., Delacauw, A., Ferrant, A., Van den Berghe, G., Bontemps, F. (2001). Resistance to 2-chloro-2’-deoxyadenosine of the human B-leukemia cell line EHEB. Clin. Cancer Res. 7, 3559-66.

[5] Van Den Neste E., Cardoen, S., Husson, B., Rosier, J.-F., Delacauw, A. , Ferrant, A. , Van den Berghe, G., Bontemps, F. (2002) 2-Chloro-2’-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes. Leukemia 16, 36-43.

[6] Van Den Neste, E., Smal, C., Cardoen, S., Delacauw, A., Frankard, J., Ferrant, A., Van den Berghe G., Bontemps, F. (2003) Activation of deoxycytidine kinase by UV-C irradiation in chronic lymphocytic leukemia B-lymphocytes. Biochem. Pharmacol 65, 573-80. 

[7] Smal, C., Cardoen, S., Bertrand L., Delacauw A., Ferrant A., Van den Berghe, G., Van Den Neste, E., Bontemps, F. (2004) Activation of deoxycytidine kinase by protein kinase inhibitors and okadaic acid in leukemic cells. Biochem. Pharmacol. 68, 95-103.

Thesis

Nucleoside analogs in chronic lymphoid malignancies: studies of the clinical effects and mechanisms of action of cladribine and fludarabine. Eric van Den Neste, 2004

Top